CALR and myeloproliferative neoplasm: Except for a slightly elevated median CD25 level on NSC in MPN patients exhibiting CALR mutations and a slightly higher median KIT level on MPN NSC in JAK2V617F+ patients, no difference in the NSC phenotype was found when comparing CALR‐mutated MPN with JAK2V617F+ MPN (Figure S5).